Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4587 participants.

Also called NCT01422616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,587 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01422616
Main results
  • Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke The New England journal of medicine, 2016-06-16 DOI, PubMed 27161018 PubMed links an erratum for this paper. Erratum: PMID 29641954
Other papers using this trial's data
  • Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study Stroke, 2022-03 DOI, PubMed 34702064
  • Body Weight in Relation to the Effectiveness of Intravenous Alteplase in Acute Ischemic Stroke: The ENCHANTED Trial Stroke, 2026-10 DOI, PubMed 42644244
  • Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial Journal of hypertension, 2021-02-01 DOI, PubMed 33031175
  • Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results Stroke, 2025-06 DOI, PubMed 40177745
  • Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial Lancet (London, England), 2019-03-02 DOI, PubMed 30739745
  • Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Cerebrovascular diseases (Basel, Switzerland), 2019 DOI, PubMed 31812956
  • Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial Neurology, 2021-03-16 DOI, PubMed 33536271, PMC8032382 PubMed links an erratum for this paper. Erratum: PMID 34045278 In the PMC Open Access subset under CC BY.
  • Patterns and Clinical Implications of Hemorrhagic Transformation After Thrombolysis in Acute Ischemic Stroke: Results From the ENCHANTED Study Neurology, 2024-12-10 DOI, PubMed 39541551
  • Smoking influences outcome in patients who had thrombolysed ischaemic stroke: the ENCHANTED study Stroke and vascular neurology, 2021-09 DOI, PubMed 33526633, PMC8485230 In the PMC Open Access subset under CC BY-NC.
  • The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes Health research policy and systems, 2019-02-13 DOI, PubMed 30760277, PMC6375185 In the PMC Open Access subset under CC BY.
  • Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target International journal of stroke : official journal of the International Stroke Society, 2022-06 DOI, PubMed 34096413
  • Twenty-Four-Hour Post-Thrombolysis NIHSS Score As the Strongest Prognostic Predictor After Acute Ischemic Stroke: ENCHANTED Study Journal of the American Heart Association, 2024-09-17 DOI, PubMed 39258531, PMC11935628 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01422616. Randomized; single masking; primary purpose treatment. Start 2012-03 (actual); primary completion 2018-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
Acronym
ENCHANTED
Intervention (Drug)
Low-dose rtPA
Intervention (Drug)
Standard-dose rtPA
Intervention (Other)
Intensive blood pressure (BP) lowering
Intervention (Other)
BP management policies
Lead sponsor
The George Institute (class: other)
Collaborator
National Health and Medical Research Council, Australia (class: other)
Collaborator
The Stroke Association, United Kingdom (class: other)
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico (class: other government)
Collaborator
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01422616
Content hash
8e779d9f37fe3a559cfa3dda79c4cc1801065b2d9a5f97dbf64d466a7e6b987b